Articles tagged with Chronic Rejection
A new Northwestern University study reveals that abnormal cells in transplanted lungs engage in harmful 'conversations' with the immune system, leading to damage and rejection. The findings provide a comprehensive roadmap for treating chronic lung allograft dysfunction and other scarring lung diseases.
Researchers at Medical University of South Carolina engineered a new type of immune cell that can precisely target and neutralize antibody-producing cells complicit in organ rejection. This strategy could level the playing field for patients with limited eligibility for organs due to high rejection rates.
A new study by Mass General Brigham researchers has identified a natural 'brake' within the innate immune system that can prevent organ transplant rejection. The discovery highlights a promising target for new therapies and offers hope for longer-lasting transplant success and reduced need for lifelong immunosuppression.
A new device developed by Northwestern University researchers can detect temperature irregularities associated with inflammation and other body responses that arise with transplant rejection. This allows for earlier intervention, improving patient outcomes and increasing the odds of preserving donated organs.
Researchers at University of Pittsburgh have discovered a type of immune cell that drives chronic organ transplant failure and uncovered pathways to improve patient outcomes. Blocking IL-15 signaling has been shown to prolong graft survival in mouse kidney recipients, offering a promising therapeutic target.
Researchers identified specific mesenchymal stromal cells within the bronchovascular bundle of lungs that play a crucial role in creating scarring through interaction with epithelial cells. These cells are thought to be triggered by immune cell attacks, leading to fibrotic scarring and rejection.
A new electronic 'nose' has been developed to detect when a lung transplant is beginning to fail, with 86% accuracy. The device uses machine learning algorithms to analyze exhaled breath patterns and identify lung diseases, offering new hope for patients diagnosed with chronic allograft dysfunction.
Researchers identified protein patterns in lung tissue from patients with end-stage bronchiolitis obliterans syndrome, revealing an epithelial/mesenchymal imbalance and increased stiffness in remodeled airways. This breakthrough study may help develop therapies to improve long-term outcomes for lung transplantation patients.
Researchers discovered a link between antibodies and aggressive lung rejection, and found targeting B cells and interleukin-6 can reduce fibrosis and rejection. This approach may lead to personalized therapies for patients with chronic rejection.
A new study published in Science Translational Medicine reveals that monitoring Zinc finger and BTB domain-containing protein 7A (ZBTB7A) can be an early predictor of chronic lung allograft dysfunction (CLAD). This discovery fills the void for a reliable marker, opening new opportunities for diagnosis and prevention.
A study has identified three proteins that can predict chronic lung rejection in transplant patients, offering new hope for early intervention and prevention. The proteins, which form a 'biosignature' of organ rejection, were found using advanced high-tech tools and analysis techniques.
Researchers found that aerosolized cyclosporine preserves lung function and reduces chronic rejection in lung transplant patients. The new study used 58 patients and found that those who received the placebo experienced a decline in lung function four times as great as those who inhaled the cyclosporine.
A pivotal study found that CyIS significantly reduces chronic rejection and prolongs survival in lung-transplant recipients, offering hope for a breakthrough therapy to address this unmet need. The study demonstrated an 84% four-year survival rate with CyIS compared to 56% with placebo.
A long-term follow-up study found that only four out of 166 children treated with tacrolimus developed chronic rejection. The patients who experienced rejection had been off immunosuppression for extended periods due to life-threatening infections or complications, but were able to recover once they resumed normal dosages.
Researchers have discovered that the old drug sirolimus can also protect blood vessels of transplanted hearts, preventing chronic rejection. The study found that sirolimus can stop proliferation of smooth-muscle cells, which build up scar tissue and block oxygen supply to the heart.
A recent study found that liver transplant patients from African American and Asian backgrounds experience lower two-year and five-year survival rates compared to their white American and Hispanic counterparts. The study suggests a need for further research into the reasons behind these disparities in patient outcomes.